RWE Oncology Market by Component (Real-world Datasets, RWE Consulting & Analytics Services), Application (Drug Development & Approvals, Market Access, Post-market Surveillance), End User & Geography – Global Forecast to 2035

The global RWE oncology market was valued at $789 million in 2024. This market is expected to reach $3.51 billion by 2035, growing from an estimated $893 million in 2025, at a CAGR of 14.7% during the forecast period of 2025–2035.

Report Overview

This report examines the global market for real-world evidence (RWE) oncology solutions, focusing on how providers are meeting the increasing need for evidence-driven cancer care, value-based healthcare approaches, and regulatory mandates for post-market surveillance. It offers a strategic analysis of market trends, projections through 2035, and a comprehensive evaluation of the competitive environment across global, regional, and country-specific levels.

Key Market Drivers & Trends

The RWE oncology solutions market is primarily driven by the growing demand for real-world evidence in drug development, increasing focus on value-based healthcare, rising cancer incidence and prevalence globally, regulatory support for RWE in healthcare decision-making, and advancements in data analytics and AI technologies. The shift towards patient-centric healthcare models, adoption of cloud-based RWE platforms, integration of genomic and molecular data, and real-time data collection and analysis are reshaping the industry. Additionally, integration with precision medicine initiatives and development of AI-powered analytics solutions are gaining significant traction, especially in developed markets with advanced healthcare infrastructure.

Key Challenges

Although the RWE oncology solutions market holds substantial growth potential, it encounters several challenges such as data privacy and security concerns, lack of standardization in data collection, and high implementation and maintenance costs. Furthermore, hurdles like limited interoperability between healthcare systems, regulatory compliance across different regions, data quality and completeness issues, and integration of disparate data sources pose significant barriers that could hinder market adoption in different parts of the world.

Growth Opportunities

The RWE oncology solutions market presents numerous avenues for high growth. Expansion in emerging markets offers substantial opportunities for market players looking to reach new customer bases. Integration with precision medicine initiatives provides another key opportunity, enhancing the accessibility of personalized cancer care. Moreover, development of AI-powered analytics solutions and partnerships between healthcare stakeholders are generating new revenue streams for solution providers as organizations seek evidence-based alternatives to traditional healthcare decision-making methods.

Market Segmentation Highlights

By Component

The Datasets segment is expected to hold the largest share of the overall RWE oncology solutions market in 2025, driven by increasing demand for comprehensive cancer data across the healthcare ecosystem. This segment includes disparate datasets (EMR/EHR/clinical data, claims & billing data, pharmacy data, cancer registries, and other disparate datasets) and integrated datasets. However, the Consulting Services segment is expected to experience significant growth during the forecast period, driven by the growing need for expertise in RWE study design, regulatory guidance, and data interpretation services.

By Application

The Market Access & Reimbursement/Coverage Decisions segment is expected to hold the largest share of the overall RWE oncology solutions market in 2025, driven by payers' increasing reliance on RWE for value-based healthcare decisions, coverage determinations, and the broad demand from insurance companies, government programs, and health systems for real-world cost-effectiveness data. However, the Drug Development & Approvals segment is expected to experience significant growth during the forecast period, driven by increasing regulatory acceptance of RWE in drug approval processes and growing pharmaceutical investment in oncology research.

By End User

The Pharmaceutical, Biotechnology, and Medical Device Companies segment is expected to hold the largest share of the overall RWE oncology solutions market in 2025, due to their substantial investment in oncology R&D and regulatory requirements for post-market surveillance. However, the Healthcare Payers segment is expected to experience notable growth during the forecast period, driven by increasing adoption of value-based care models and the need for cost-effectiveness evidence in coverage decisions.

By Geography

North America is expected to hold the largest share of the global RWE oncology solutions market in 2025, driven by advanced healthcare infrastructure, strong regulatory support for RWE, well-established pharmaceutical industry, and favorable reimbursement policies.

Additionally, high cancer incidence rates and mature data analytics capabilities contribute significantly to market dominance. Europe follows as a significant market, bolstered by stringent regulatory requirements and increasing adoption of digital health technologies. However, Asia-Pacific is witnessing the fastest growth rate during the forecast period, primarily driven by rising cancer burden, expanding healthcare infrastructure, growing pharmaceutical investments, and increasing awareness about precision medicine approaches.

Competitive Landscape

The global RWE oncology solutions market is characterized by a diverse competitive environment, comprising established healthcare data analytics companies, pharmaceutical service providers, technology giants, and specialized oncology data solution providers, each adopting unique approaches to advancing RWE capabilities.

Within this landscape, solution providers are segmented into industry leaders, market differentiators, vanguards, and contemporary stalwarts, with each group implementing distinct strategies to sustain their competitive edge. Leading companies are prioritizing integrated platforms that merge comprehensive oncology datasets with advanced analytics capabilities, while also addressing data standardization challenges specific to various regions.

The key players operating in the global RWE oncology solutions market include IQVIA Holdings Inc., Veracyte Inc., Flatiron Health Inc., IBM Corporation, Oracle Corporation, SAS Institute Inc., ICON plc, Parexel International Corporation, Syneos Health Inc., Cognizant Technology Solutions Corporation, UnitedHealth Group Incorporated, Anthem Inc., Clinigen Group plc, PerkinElmer Inc., and Tempus Labs Inc., among others.

RWE Oncology Solutions Market Report Summary

Key Questions Answered in the Report: